Eman Mostafa Nassef, Hemmat Ahmed Elabd, Hala Mohamed Elzomor, Basma Mohamed Mohamed Ali El Nagger, Amira Shahin Ibrahim, Amal Hussein Ibrahim, Hend Gamal Kotb, Donia Ahmed Hassan, Rasha Elsayed Mohamed Abd ElAziz, Eman El Sayed Mohamed
{"title":"血清胶原蛋白三螺旋重复序列含1水平与类风湿关节炎的放射学影响和疾病活动性有关。","authors":"Eman Mostafa Nassef, Hemmat Ahmed Elabd, Hala Mohamed Elzomor, Basma Mohamed Mohamed Ali El Nagger, Amira Shahin Ibrahim, Amal Hussein Ibrahim, Hend Gamal Kotb, Donia Ahmed Hassan, Rasha Elsayed Mohamed Abd ElAziz, Eman El Sayed Mohamed","doi":"10.2147/OARRR.S391494","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Rheumatoid arthritis (RA) is a common systemic inflammatory disease. Collagen triple helix repeat containing-1 (CTHRC1) is a unique gene product able to reduce collagen deposition. The present study aimed to assess CTHRC1 level in RA patients and to uncover its relation to clinical, laboratory and radiological findings.</p><p><strong>Methods: </strong>The study included 60 adult RA patients. In addition, there were 60 control subjects who included patients with osteoarthritis (n = 20) and reactive arthritis (n = 20) and healthy controls (n = 20). Serum CTHRC1 levels were assessed by Enzyme-Linked Immunosorbent Assay (ELISA). Disease activity was calculated using the Disease Activity Score (DAS28-CRP). Radiological damage was evaluated using the Simple Erosion Narrowing Score (SENS).</p><p><strong>Results: </strong>There was significantly higher serum CTHRC1 levels in RA patients when compared to OA, ReA and control groups [median (IQR): 4.66 (1.68-11.7) versus 1.88 (1.14-2.94), 1.55 (0.98-3.15) and 1.14 (0.85-1.3) mg/dL, respectively, p < 0.001]. There was significantly higher CTHRC1 levels in patients with higher disease activity [median (IQR): 2.23 (1.4-4.73) versus 6.55 (4.66-12.0) mg/dL, p = 0.004]. Patients with higher SENS had significantly higher CTHRC1 [median (IQR): 1.99 (1.4-4.66) versus 9.75 (4.39-12.63) mg/dL, p < 0.001] and DAS28 [median (IQR): 4.25 (2.9-5.2) versus 5.4 (4.65-5.8), p = 0.01].</p><p><strong>Conclusion: </strong>Serum CTHRC1 levels are related to disease severity and radiological affection in RA patients.</p>","PeriodicalId":45545,"journal":{"name":"Open Access Rheumatology-Research and Reviews","volume":"14 ","pages":"291-299"},"PeriodicalIF":1.7000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/85/66/oarrr-14-291.PMC9748116.pdf","citationCount":"0","resultStr":"{\"title\":\"Serum Collagen Triple Helix Repeat Containing-1 Levels are Related to Radiological Affection and Disease Activity in Rheumatoid Arthritis.\",\"authors\":\"Eman Mostafa Nassef, Hemmat Ahmed Elabd, Hala Mohamed Elzomor, Basma Mohamed Mohamed Ali El Nagger, Amira Shahin Ibrahim, Amal Hussein Ibrahim, Hend Gamal Kotb, Donia Ahmed Hassan, Rasha Elsayed Mohamed Abd ElAziz, Eman El Sayed Mohamed\",\"doi\":\"10.2147/OARRR.S391494\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Rheumatoid arthritis (RA) is a common systemic inflammatory disease. Collagen triple helix repeat containing-1 (CTHRC1) is a unique gene product able to reduce collagen deposition. The present study aimed to assess CTHRC1 level in RA patients and to uncover its relation to clinical, laboratory and radiological findings.</p><p><strong>Methods: </strong>The study included 60 adult RA patients. In addition, there were 60 control subjects who included patients with osteoarthritis (n = 20) and reactive arthritis (n = 20) and healthy controls (n = 20). Serum CTHRC1 levels were assessed by Enzyme-Linked Immunosorbent Assay (ELISA). Disease activity was calculated using the Disease Activity Score (DAS28-CRP). Radiological damage was evaluated using the Simple Erosion Narrowing Score (SENS).</p><p><strong>Results: </strong>There was significantly higher serum CTHRC1 levels in RA patients when compared to OA, ReA and control groups [median (IQR): 4.66 (1.68-11.7) versus 1.88 (1.14-2.94), 1.55 (0.98-3.15) and 1.14 (0.85-1.3) mg/dL, respectively, p < 0.001]. There was significantly higher CTHRC1 levels in patients with higher disease activity [median (IQR): 2.23 (1.4-4.73) versus 6.55 (4.66-12.0) mg/dL, p = 0.004]. Patients with higher SENS had significantly higher CTHRC1 [median (IQR): 1.99 (1.4-4.66) versus 9.75 (4.39-12.63) mg/dL, p < 0.001] and DAS28 [median (IQR): 4.25 (2.9-5.2) versus 5.4 (4.65-5.8), p = 0.01].</p><p><strong>Conclusion: </strong>Serum CTHRC1 levels are related to disease severity and radiological affection in RA patients.</p>\",\"PeriodicalId\":45545,\"journal\":{\"name\":\"Open Access Rheumatology-Research and Reviews\",\"volume\":\"14 \",\"pages\":\"291-299\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/85/66/oarrr-14-291.PMC9748116.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Open Access Rheumatology-Research and Reviews\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2147/OARRR.S391494\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Access Rheumatology-Research and Reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/OARRR.S391494","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:类风湿关节炎(RA)是一种常见的全身性炎症性疾病。胶原蛋白三螺旋重复序列-1 (CTHRC1)是一种独特的能够减少胶原沉积的基因产物。本研究旨在评估RA患者的CTHRC1水平，并揭示其与临床、实验室和放射学表现的关系。方法:研究对象为60例成人RA患者。此外，还有60名对照受试者，包括骨关节炎患者(n = 20)和反应性关节炎患者(n = 20)和健康对照组(n = 20)。采用酶联免疫吸附试验(ELISA)检测血清CTHRC1水平。使用疾病活动性评分(DAS28-CRP)计算疾病活动性。使用简单侵蚀缩小评分(SENS)评估放射损伤。结果:RA患者血清CTHRC1水平显著高于OA、ReA和对照组[中位数(IQR)分别为4.66(1.68-11.7)、1.88(1.14-2.94)、1.55(0.98-3.15)和1.14 (0.85-1.3)mg/dL, p < 0.001]。疾病活动性越高的患者CTHRC1水平越高[中位数(IQR): 2.23 (1.4-4.73) vs 6.55 (4.66-12.0) mg/dL, p = 0.004]。SENS较高的患者CTHRC1[中位数(IQR): 1.99(1.4-4.66)对9.75 (4.39-12.63)mg/dL, p < 0.001]和DAS28[中位数(IQR): 4.25(2.9-5.2)对5.4 (4.65-5.8)，p = 0.01]显著升高。结论:RA患者血清CTHRC1水平与病情严重程度及影像学影响相关。
Serum Collagen Triple Helix Repeat Containing-1 Levels are Related to Radiological Affection and Disease Activity in Rheumatoid Arthritis.
Background: Rheumatoid arthritis (RA) is a common systemic inflammatory disease. Collagen triple helix repeat containing-1 (CTHRC1) is a unique gene product able to reduce collagen deposition. The present study aimed to assess CTHRC1 level in RA patients and to uncover its relation to clinical, laboratory and radiological findings.
Methods: The study included 60 adult RA patients. In addition, there were 60 control subjects who included patients with osteoarthritis (n = 20) and reactive arthritis (n = 20) and healthy controls (n = 20). Serum CTHRC1 levels were assessed by Enzyme-Linked Immunosorbent Assay (ELISA). Disease activity was calculated using the Disease Activity Score (DAS28-CRP). Radiological damage was evaluated using the Simple Erosion Narrowing Score (SENS).
Results: There was significantly higher serum CTHRC1 levels in RA patients when compared to OA, ReA and control groups [median (IQR): 4.66 (1.68-11.7) versus 1.88 (1.14-2.94), 1.55 (0.98-3.15) and 1.14 (0.85-1.3) mg/dL, respectively, p < 0.001]. There was significantly higher CTHRC1 levels in patients with higher disease activity [median (IQR): 2.23 (1.4-4.73) versus 6.55 (4.66-12.0) mg/dL, p = 0.004]. Patients with higher SENS had significantly higher CTHRC1 [median (IQR): 1.99 (1.4-4.66) versus 9.75 (4.39-12.63) mg/dL, p < 0.001] and DAS28 [median (IQR): 4.25 (2.9-5.2) versus 5.4 (4.65-5.8), p = 0.01].
Conclusion: Serum CTHRC1 levels are related to disease severity and radiological affection in RA patients.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
